These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Diuretic effect and disposition of furosemide in cystic fibrosis. Prandota J; Smith IJ; Hilman BC; Wilson JT Eur J Clin Pharmacol; 1991; 40(4):333-41. PubMed ID: 2050167 [TBL] [Abstract][Full Text] [Related]
7. Variable furosemide absorption and poor predictability of response in elderly patients. Murray MD; Haag KM; Black PK; Hall SD; Brater DC Pharmacotherapy; 1997; 17(1):98-106. PubMed ID: 9017769 [TBL] [Abstract][Full Text] [Related]
8. Absorption of high dose furosemide (frusemide) in congestive heart failure. Van Meyel JJ; Gerlag PG; Smits P; Russel FG; Tan Y; Van Ginneken CA; Gribnau FW Clin Pharmacokinet; 1992 Apr; 22(4):308-18. PubMed ID: 1606790 [TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics of furosemide in man after intravenous and oral administration. Application of moment analysis. Hammarlund MM; Paalzow LK; Odlind B Eur J Clin Pharmacol; 1984; 26(2):197-207. PubMed ID: 6723758 [TBL] [Abstract][Full Text] [Related]
10. Bioavailability, pharmacokinetics, and pharmacodynamics of torsemide and furosemide in patients with congestive heart failure. Vargo DL; Kramer WG; Black PK; Smith WB; Serpas T; Brater DC Clin Pharmacol Ther; 1995 Jun; 57(6):601-9. PubMed ID: 7781259 [TBL] [Abstract][Full Text] [Related]
11. Furosemide kinetics in renal failure. Tilstone WJ; Fine A Clin Pharmacol Ther; 1978 Jun; 23(6):644-50. PubMed ID: 648078 [TBL] [Abstract][Full Text] [Related]
12. Flumazenil disposition and elimination in cirrhosis. Janssen U; Walker S; Maier K; von Gaisberg U; Klotz U Clin Pharmacol Ther; 1989 Sep; 46(3):317-23. PubMed ID: 2505960 [TBL] [Abstract][Full Text] [Related]
13. The changes in renal function after a single dose of intravenous furosemide in patients with compensated liver cirrhosis. Assy N; Kayal M; Mejirisky Y; Gorenberg M; Hussein O; Schlesinger S BMC Gastroenterol; 2006 Nov; 6():39. PubMed ID: 17134488 [TBL] [Abstract][Full Text] [Related]
15. Elimination of furosemide in healthy subjects and in those with renal failure. Beermann B; Dalén E; Lindström B Clin Pharmacol Ther; 1977 Jul; 22(1):70-8. PubMed ID: 872498 [TBL] [Abstract][Full Text] [Related]
16. Absorption and disposition of furosemide in congestive heart failure. Brater DC; Seiwell R; Anderson S; Burdette A; Dehmer GJ; Chennavasin P Kidney Int; 1982 Aug; 22(2):171-6. PubMed ID: 7132061 [TBL] [Abstract][Full Text] [Related]
17. Sublingual administration of furosemide: new application of an old drug. Haegeli L; Brunner-La Rocca HP; Wenk M; Pfisterer M; Drewe J; Krähenbühl S Br J Clin Pharmacol; 2007 Dec; 64(6):804-9. PubMed ID: 17875188 [TBL] [Abstract][Full Text] [Related]
18. Ranitidine disposition in severe hepatic cirrhosis. Gonzalez-Martin G; Paulos C; Veloso B; Chesta J; Novoa X; Arancibia A Int J Clin Pharmacol Ther Toxicol; 1987 Mar; 25(3):139-42. PubMed ID: 3557740 [TBL] [Abstract][Full Text] [Related]
19. A study on furosemide disposition in man. Zhu JB; Koizumi T J Pharmacobiodyn; 1987 Aug; 10(8):370-6. PubMed ID: 3694431 [TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics of metoclopramide in patients with liver cirrhosis. Magueur E; Hagege H; Attali P; Singlas E; Etienne JP; Taburet AM Br J Clin Pharmacol; 1991 Feb; 31(2):185-7. PubMed ID: 2049236 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]